Study: NCT03011528

Intervention type: DRUG
Group type: OTHER
Intervention: VDC-IE x2
Description: Week 1, 5, 9 and week 13:~* Vincristine, IV, D1, 1.5mg/m²~* Doxorubicine, IV, D1-D2, 37.5mg/m²~* Cyclophosphamide, IV, D1, 1.2g/m²~Week 3, 7, 11 and week 15:~* Ifosfamide, IV, D15 to D19, 1.8g/m²/d~* Etoposide, IV, D15 to D19, 100mg/m²/d

Intervention type: DRUG
Group type: OTHER
Intervention: VDC-IE x2
Description: Week 1, 5, 9 and week 13:~* Vincristine, IV, D1, 1.5mg/m²~* Doxorubicine, IV, D1-D2, 37.5mg/m²~* Cyclophosphamide, IV, D1, 1.2g/m²~Week 3, 7, 11 and week 15:~* Ifosfamide, IV, D15 to D19, 1.8g/m²/d~* Etoposide, IV, D15 to D19, 100mg/m²/d

Intervention type: DRUG
Group type: OTHER
Intervention: VDC-IE
Description: Week 1 and week 5:~* Vincristine, IV, D1, 1.5mg/m²~* Doxorubicine, IV, D1-D2, 37.5mg/m²~* Cyclophosphamide, IV, D1, 1.2g/m²~Week 3, and week 7:~* Ifosfamide, IV, D15 to D19, 1.8g/m²/d~* Etoposide, IV, D15 to D19, 100mg/m²/d

Intervention type: DRUG
Group type: OTHER
Intervention: VDC-IE
Description: Week 1 and week 5:~* Vincristine, IV, D1, 1.5mg/m²~* Doxorubicine, IV, D1-D2, 37.5mg/m²~* Cyclophosphamide, IV, D1, 1.2g/m²~Week 3, and week 7:~* Ifosfamide, IV, D15 to D19, 1.8g/m²/d~* Etoposide, IV, D15 to D19, 100mg/m²/d

Intervention type: DRUG
Group type: OTHER
Intervention: TEMIRI
Description: Week 9, 12, 15 and week 18:~* Temozolomide, PO, D1 to D5, 150mg/m²/d~* Irinotecan, IV, D1 to D5, 50mg/m²/d

Intervention type: DRUG
Group type: OTHER
Intervention: TEMIRI
Description: Week 9, 12, 15 and week 18:~* Temozolomide, PO, D1 to D5, 150mg/m²/d~* Irinotecan, IV, D1 to D5, 50mg/m²/d

Intervention type: DRUG
Group type: OTHER
Intervention: Consolidation BuMel
Description: After induction phase and local treatment (surgery and/or radiotherapy) and before PBSC:~* Busulfan, IV, D-5 to D-2, dosa according to the weight~* Melphalan, IV, D-1, 140 mg/m²~Peripheral Blood Stem Cell infusion:~- PBSC infusion, D0, at least 3.10\^6 CD34/kg

Intervention type: DRUG
Group type: OTHER
Intervention: Consolidation BuMel
Description: After induction phase and local treatment (surgery and/or radiotherapy) and before PBSC:~* Busulfan, IV, D-5 to D-2, dosa according to the weight~* Melphalan, IV, D-1, 140 mg/m²~Peripheral Blood Stem Cell infusion:~- PBSC infusion, D0, at least 3.10\^6 CD34/kg

Intervention type: DRUG
Group type: OTHER
Intervention: Consolidation BuMel
Description: After induction phase and local treatment (surgery and/or radiotherapy) and before PBSC:~* Busulfan, IV, D-5 to D-2, dosa according to the weight~* Melphalan, IV, D-1, 140 mg/m²~Peripheral Blood Stem Cell infusion:~- PBSC infusion, D0, at least 3.10\^6 CD34/kg

Intervention type: DRUG
Group type: OTHER
Intervention: Consolidation BuMel
Description: After induction phase and local treatment (surgery and/or radiotherapy) and before PBSC:~* Busulfan, IV, D-5 to D-2, dosa according to the weight~* Melphalan, IV, D-1, 140 mg/m²~Peripheral Blood Stem Cell infusion:~- PBSC infusion, D0, at least 3.10\^6 CD34/kg

Intervention type: DRUG
Group type: OTHER
Intervention: Maintenance
Description: \* 1st year : VC~* Vinblastine, IV, 3mg/m², once a week (except during radiotherapy: 1mg/m², 3 times a week)~* Cyclophosphamide, PO, 25mg/m² continuously

Intervention type: DRUG
Group type: OTHER
Intervention: Maintenance
Description: \* 1st year : VC~* Vinblastine, IV, 3mg/m², once a week (except during radiotherapy: 1mg/m², 3 times a week)~* Cyclophosphamide, PO, 25mg/m² continuously

Intervention type: DRUG
Group type: OTHER
Intervention: Maintenance
Description: \* 1st year : VC~* Vinblastine, IV, 3mg/m², once a week (except during radiotherapy: 1mg/m², 3 times a week)~* Cyclophosphamide, PO, 25mg/m² continuously

Intervention type: DRUG
Group type: OTHER
Intervention: Maintenance
Description: \* 1st year : VC~* Vinblastine, IV, 3mg/m², once a week (except during radiotherapy: 1mg/m², 3 times a week)~* Cyclophosphamide, PO, 25mg/m² continuously

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Local treatment by surgery
Description: Surgical excision of whole site of the primary tumour and metastatic sites (outside pulmonary sites) can take place before or after the high dose consolidation chemotherapy. Radiotherapy can be added

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Local treatment by surgery
Description: Surgical excision of whole site of the primary tumour and metastatic sites (outside pulmonary sites) can take place before or after the high dose consolidation chemotherapy. Radiotherapy can be added

Intervention type: RADIATION
Group type: OTHER
Intervention: Local treatment by radiotherapy
Description: Radiotherapy of whole site of the primary tumour and metastatic sites (outside pulmonary sites) can take place before or after the high dose consolidation chemotherapy

Intervention type: RADIATION
Group type: OTHER
Intervention: Local treatment by radiotherapy
Description: Radiotherapy of whole site of the primary tumour and metastatic sites (outside pulmonary sites) can take place before or after the high dose consolidation chemotherapy

Intervention type: RADIATION
Group type: OTHER
Intervention: Local treatment by radiotherapy
Description: Radiotherapy of whole site of the primary tumour and metastatic sites (outside pulmonary sites) can take place before or after the high dose consolidation chemotherapy